BioCentury | Feb 28, 2015
Company News

TaiMed's ibalizumab gets breakthrough designation

...Inc. unit of Roche (SIX:ROG; OTCQX:RHBBY), which gained the compound through its 2007 acquisition of Tanox Inc....
BioCentury | Jul 14, 2014
Product Development

Less unSERDainty

...is only Genentech's second acquisition in its 38-year history: It paid roughly $919 million for Tanox Inc....
...that deal was to simplify marketing arrangements for asthma drug Xolair omalizumab, which Genentech and Tanox...
BioCentury | Jul 14, 2014
Company News

Genentech Inc, Roche, Seragon deal

...deal will be the unit’s second acquisition; the first was infectious disease and oncology company Tanox Inc....
BioCentury | Jul 3, 2014
Top Story

Genentech to acquire Seragon

...deal will be the unit's second acquisition; the first was infectious disease and oncology company Tanox Inc....
BioCentury | May 12, 2014
Clinical News

Ibalizumab regulatory update

...commercialize ibalizumab from Roche's Genentech unit, which gained the compound through its 2007 acquisition of Tanox Inc....
BioCentury | May 6, 2014
Company News

Chinese manufactured biologic gets approval for U.S. use

...Inc. unit of Roche (SIX:ROG; OTCQX:RHBBY), which gained the compound through its 2007 acquisition of Tanox Inc....
BioCentury | Aug 27, 2013
Clinical News

Roche reports Phase II dry AMD data

...2009 acquisition of Genentech Inc. Genentech had acquired the compound through its 2006 acquisition of Tanox Inc....
BioCentury | Nov 1, 2010
Finance

IPOs in Sequence

...Tanox Inc. in 2000 at $244.2 million. At IPO, Talecris was valued at $2.3 billion, and Tanox...
BioCentury | Jul 12, 2010
Strategy

Biogen Idec's Agenda

...which nine were sizable and three were valued above $500 million, including its acquisition of Tanox Inc....
BioCentury | Feb 8, 2010
Finance

Ironed Out

...The offering does give Ironwood the second largest post-IPO valuation for a development-stage company, behind Tanox Inc....
Items per page:
1 - 10 of 287
BioCentury | Feb 28, 2015
Company News

TaiMed's ibalizumab gets breakthrough designation

...Inc. unit of Roche (SIX:ROG; OTCQX:RHBBY), which gained the compound through its 2007 acquisition of Tanox Inc....
BioCentury | Jul 14, 2014
Product Development

Less unSERDainty

...is only Genentech's second acquisition in its 38-year history: It paid roughly $919 million for Tanox Inc....
...that deal was to simplify marketing arrangements for asthma drug Xolair omalizumab, which Genentech and Tanox...
BioCentury | Jul 14, 2014
Company News

Genentech Inc, Roche, Seragon deal

...deal will be the unit’s second acquisition; the first was infectious disease and oncology company Tanox Inc....
BioCentury | Jul 3, 2014
Top Story

Genentech to acquire Seragon

...deal will be the unit's second acquisition; the first was infectious disease and oncology company Tanox Inc....
BioCentury | May 12, 2014
Clinical News

Ibalizumab regulatory update

...commercialize ibalizumab from Roche's Genentech unit, which gained the compound through its 2007 acquisition of Tanox Inc....
BioCentury | May 6, 2014
Company News

Chinese manufactured biologic gets approval for U.S. use

...Inc. unit of Roche (SIX:ROG; OTCQX:RHBBY), which gained the compound through its 2007 acquisition of Tanox Inc....
BioCentury | Aug 27, 2013
Clinical News

Roche reports Phase II dry AMD data

...2009 acquisition of Genentech Inc. Genentech had acquired the compound through its 2006 acquisition of Tanox Inc....
BioCentury | Nov 1, 2010
Finance

IPOs in Sequence

...Tanox Inc. in 2000 at $244.2 million. At IPO, Talecris was valued at $2.3 billion, and Tanox...
BioCentury | Jul 12, 2010
Strategy

Biogen Idec's Agenda

...which nine were sizable and three were valued above $500 million, including its acquisition of Tanox Inc....
BioCentury | Feb 8, 2010
Finance

Ironed Out

...The offering does give Ironwood the second largest post-IPO valuation for a development-stage company, behind Tanox Inc....
Items per page:
1 - 10 of 287